Interleukin-10 Does Not Mediate the Inhibitory Effect of PDE-4 Inhibitors Other cAMP-Elevating Drugs on Lipopolysaccharide-Induced Tumors Necrosis Factor-α Generation from Human Peripheral Blood Monocytes

Cell Biochemistry and Biophysics

Volumn 29, Issue 1-2, 1998, Pages 179-201

  Seldon, Paul M ^a   Barnes, Peter J ^a   Giembycz, Mark A ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDONE DERIVATIVE; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; 8 BROMO CYCLIC AMP; CYCLIC AMP; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PROSTAGLANDIN E2; ROLIPRAM; SALBUTAMOL; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOSYNTHESIS; CELL COUNT; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; IMMUNOLOGY; METABOLISM; MONOCYTE; PHYSIOLOGY;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; 8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ALBUTEROL; ANTIBODIES, MONOCLONAL; CELL COUNT; CELLS, CULTURED; CYCLIC AMP; DINOPROSTONE; HUMANS; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MONOCYTES; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; ROLIPRAM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031616317     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02737835     Document Type: Article

References (36)

1. Giembycz, M. A., Dent, G., and Souness, J. E. (1997) Theophylline and isoenzyme-selective phosphodiesterase inhibitors, in Allergy and Allergic Diseases (Kay, A. B., ed.), Blackwell Scientific, pp. 531-567.
2. Torphy, T. J. and Undem, B. J. (1991) Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. i 46, 512-523.
3. Giembycz, M. A. (1992) Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem. Pharmacol. 43, 2041-2051.
4. Giembycz, M. A. and Dent, G. (1992) Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin. Exp. Allergy 22, 337-344.
5. Nicholson, C. D. and Shahid, M. (1994) Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes - their potential utility in the therapy of asthma. Pulmonary Pharmacol. 7, 1-17.
6. Dent, G. and Giembycz, M. A. (1995) Selective phosphodiesterase inhibitors in the therapy of asthma. Clin. Immunother. 3, 423-437.
7. Dent, G. and Giembycz, M. A. (1996) Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? Thorax 51, 647-649.
8. Hughes, B., Owens, R., Perry, M., Warrellow, G., and Allen, R. (1997) PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs. Drug Discovery Today. 2, 89-101.
9. Seldon, P. M., Barnes, P. J., Meja, K., and Giembycz, M. A. (1995) Suppression of lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol. Pharmacol. 48, 747-757.
10. Prabhakar, U., Lipshutz, D., Bartus, J. O., Slivjak, M. J., Smith, E. F., Lee, J. C., et al. (1994) Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16, 805-816.
11. Molnar-Kimber, K., Yonno, L., Heaslip, R., and Weichman, B. M. (1993) Modulation of TNFa and IL-1b from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 39, C77-C79.
12. Semmler, J., Gebert, U., Eisenhut, T., Moeller, J., Schonharting, M. M., Allera, A., et al. (1993) Xanthine derivatives: comparison between suppression of tumor necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 78, 520-525.
13. Stricter, R. M., Kunkel, S. L., and Bone, R. C. (1993) Role of tumor necrosis factor-α in disease states and inflammation. Crit. Care Med. 21, S447-S468.
14. Sekut, L., Yarnall, D., Stimpson, S. A., Noel, L. S., Bateman Fite, R., Clark, R. L., Brackeen, M. F., Menius, J. A., Jr., and Connolly, K. M. (1995) Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin. Exp. Immunol. 100, 126-132.
15. Genain, C. P., Roberts, T., Davis, R.L., Nguyen, M. H., Uccelli, A., Faulds, D., Li, Y., Hedgpeth, J., and Hauser, S. L. (1995) Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA 92, 3601-3605.
16. Sommer, N., Loschmann, P. A., Northoff, G. H., Weller, M., Steinbrecher, A., Steinbach, J. P., Lichtenfels, R., Meyermann, R., Riethmuller, A., Fontana, A., et al. (1995) The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1, 244-248.
17. Giembycz, M. A. and Souness, J. E. (1996) Phosphodiesterase IV inhibitors as potential therapeutic agents in allergic disease, in Immunopharmacology of Allergic Diseases (Townley, R. G. and Agarwal, D. K., eds.), Marcel-Dekker, NY, pp. 523-560.
18. Dinter, H., Onuffer, J., Faulds, D., and Perez, H. D. (1997) Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis. J. Mol. Med. 75, 95-102.
19. Kambayashi, T., Jacob, C. O., Zhou, D., Mazurek, N., Fong, M., and Strassmann, G. (1995) Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. 155, 4909-4916.
20. 2. J. Exp. Med. 180, 2365-2370.
21. Grundmann, H. J., Hahnle, U., Hegenscheid, B., Sahlmuller, G., Bienzle, U., and Blitstein Willinger, E. (1992) Inhibition of endotoxin-induced macrophage tumor necrosis factor expression by a prostacyclin analogue and its beneficial effect in experimental lipopolysaccharide intoxication. J. Infect. Dis. 165, 501-505.
22. Arai, T., Hiromatsu, K., Kobayashi, N., Takano, M., Ishida, H., Nimura, Y., and Yoshikai, Y. (1995) IL-10 is involved in the protective effect of dibutyryl cyclic adenosine monophosphate on endotoxin-induced inflammatory liver injury. J. Immunol. 155, 5743-5749.
23. Jilg, S., Barsig, J., Leist, M., Kusters, S., Volk, H. D., and Wendel, A. (1996) Enhanced release of interleukin-10 and soluble tumor necrosis factor receptors as novel principles of methylxanthine action in murine models of endotoxic shock. J. Pharmacol. Exp. Ther. 278, 421-431.
24. Gantner, F., Kusters, S., Wendel, A., Hatzelmann, A., Schudt, C., and Tiegs, G. (1997) Protection from T-cell-mediated murine liver failure by phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 280, 53-60.
25. Pretolani, M. and Goldman, M. (1997) IL-10: a potential therapy for allergic inflammation? Immunol. Today 18, 277-280.
26. Schreiber, S., Heinig, T., Thiele, H. G., and Raedler, A. (1995) Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108, 1434-1444.
27. Kim, J. M., Brannan, C. I., Copeland, N. G., Jenkins, N. A., Khan, T. A., and Moore, K. W. (1992) Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J. Immunol. 148, 3618-3623.
28. Bogdan, C., Paik, J., Vodovotz, Y., and Nathan, C. (1992) Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. J. Biol. Chem. 267, 23,301-23,308.
29. Platzer, C., Volk, H. D., and Platzer, M. (1994) 5′ noncoding sequence of human IL-10 gene obtained by oligo-cassette PCR walking. DNA Seq. 4, 399-401.
30. Platzer, C., Meisel, C., Vogt, K., Platzer, M., and Volk, H. D. (1995) Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int. Immunol. 7, 517-523.
31. de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M. G., te Velde, A., Figdor, C., Johnson, K., Kastelein, R., Yssel, H., and de Vries, J. E. (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen- presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174, 915-924.
32. Wanidworanun, C. and Strober, W. (1993) Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J. Immunol. 151, 6853-6861.
33. de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., and de Vries, J. E. (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174, 1209-1220.
34. Armstrong, L., Jordan, N., and Millar, A. (1996) Interleukin 10 (IL-10) regulation of tumor necrosis factor alpha (TNF-αlpha) from human alveolar macrophages and peripheral blood monocytes. Thorax 51, 143-149.
35. Seldon, P. M., Barnes, P. J., and Giembycz, M. A. (1996) The inhibitory effect of cyclic AMP-elevating drugs on LPS-induced TNFα generation is not mediated by IL-10 [Abstract]. Br. J. Pharmacol. 119, 159P.
36. Donnelly, R. P., Freeman, S. L., and Hayes, M. P. (1995) Inhibition of IL-10 expression by IFN-gamma up-regulates transcription of TNF-αlpha in human monocytes. J. Immunol. 155, 1420-1427.